← All indications
Urticaria
A vascular reaction of the skin characterized by erythema and wheal formation due to localized increase of vascular permeability. The causative mechanism may be allergy, infection, or stress.
Subtype terms (3)
More specific conditions that are subtypes of Urticaria in the MeSH hierarchy.
- Angioedema
30 drugs (22 approved, 8 experimental)
- Chronic Urticaria
61 drugs (29 approved, 32 experimental)
- Cold Urticaria
Drugs by status
Approved for this indication (16)
Phase 4 trials (5)
Phase 3 trials (5)
Phase 2 trials (22)
Phase 1 trials (8)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (57)
- Roche
- Lotus Pharmaceutical
- Menarini Group
- National Institute of Allergy and Infectious Diseases (NIAID)
- Bernstein Clinical Research Center
- Grupo de Alergología Clínica y Experimental
- Hoosier Cancer Research Network
- Hospital Avicenne
- Johns Hopkins University
- Liaocheng People's Hospital
- Postgraduate Institute of Medical Education and Research
- Shandong Provincial Hospital
- Shandong Provincial Institute of Dermatology and Venereology
- Universidad de Antioquia
- University of Kansas
- University of Bordeaux
- Association Asthma, Bulgaria
- University of Colorado, Denver
- University of Modena and Reggio Emilia
- CHU Henri Mondor
- Shandong Province Qianfoshan Hospital
- University of Limoges
- Jinan University
- CH VICTOR DUPOUY - ARGENTEUIL
- HIA SAINTE ANNE - TOULON
- HOPITAL LARREY - TOULOUSE
- CHR LA MILETRIE
- CHI DE CORNOUAILLE - QUIMPER CEDEX
- CH DE CHALONS EN CHAMPAGNE - CHALONS EN CHAMPAGNE CEDEX
- HOPITAL CAREMEAU
- +27 more
Organization Involved with Phase 3 Indications (19)
- Regeneron
- Sanofi
- Celltrion
- Faes Farma, S.A.
- JDP Therapeutics, Inc.
- J. Uriach and Company
- Chang Gung University
- Universidad Complutense de Madrid
- University of Tehran
- University of Bern
- Tel Aviv University
- University of Utah
- François Rabelais University
- University of Toulouse
- Universitair Ziekenhuis Gent
- SZPITAL SPECJALISTYCZNY IM.S.
- Adverse Drug Reactions, Advice and Consulting ADR-AC
- Essex Pharma
- Assistance Publique - Hôpitaux de Paris
Organization Involved with Phase 2 Indications (31)
- Pierre Fabre
- Bristol-Myers Squibb
- AstraZeneca
- Eli Lilly
- Allakos, Inc.
- Clinuvel Pharmaceuticals Limited
- R-Pharm
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- Barnsley Hospital
- Hospital General Universitario Gregorio Marañon
- Hospital Universitario Central de Asturias
- University of Dundee
- University of Melbourne
- University of Zurich
- Uppsala University
- Salford Royal Foundation NHS Trust
- Worldwide Clinical Trials
- Proinnovera GmbH
- Karolinska Institute
- Hospital Joan XXIII de Tarragona, Tarragona, Spain
- University of Barcelona
- Universidad Autonoma de Barcelona
- Clinica Universidad de Navarra
- Hospital Clinico Lozano Blesa
- Barnsley Hospital NHS Foundation Trust
- University of Western Australia
- Government of France
- University of Franche-Comté
- IQVIA
- Kiniksa Pharmaceuticals, Ltd.
- +1 more
Organization Involved with Phase 1 Indications (14)
- Celldex Therapeutics
- GlaxoSmithKline
- Hanlim Pharm. Co., Ltd.
- United BioPharma
- Celal Bayar University
- Ege University
- Korea University
- Translational Research Institute for Metabolism and Diabetes, Florida
- Mayo Clinic
- Algorithme Pharma Inc
- The Scientific and Technological Research Council of Turkey
- Government of Canada
- Atlantic Provinces Dermatology Association
- UBP Greater China (Shanghai) Co., Ltd
Organization Involved with Other Experimental Indications (6)